FNCH vs. CLLS, PLRX, OCX, ANIX, CLYM, SNTI, GALT, GNTA, ANRO, and TNYA
Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Cellectis (CLLS), Pliant Therapeutics (PLRX), OncoCyte (OCX), Anixa Biosciences (ANIX), Climb Bio (CLYM), Senti Biosciences (SNTI), Galectin Therapeutics (GALT), Genenta Science (GNTA), Alto Neuroscience (ANRO), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry.
Finch Therapeutics Group vs.
Finch Therapeutics Group (NASDAQ:FNCH) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations.
Finch Therapeutics Group has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500.
Finch Therapeutics Group has higher earnings, but lower revenue than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
Cellectis received 405 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 64.95% of users gave Cellectis an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote.
21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cellectis has a consensus price target of $6.67, suggesting a potential upside of 328.72%. Given Cellectis' stronger consensus rating and higher possible upside, analysts plainly believe Cellectis is more favorable than Finch Therapeutics Group.
Finch Therapeutics Group has a net margin of 0.00% compared to Cellectis' net margin of -234.39%. Finch Therapeutics Group's return on equity of -69.14% beat Cellectis' return on equity.
In the previous week, Cellectis had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Cellectis and 0 mentions for Finch Therapeutics Group. Cellectis' average media sentiment score of 0.59 beat Finch Therapeutics Group's score of 0.00 indicating that Cellectis is being referred to more favorably in the news media.
Summary
Cellectis beats Finch Therapeutics Group on 13 of the 18 factors compared between the two stocks.
Get Finch Therapeutics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Finch Therapeutics Group Competitors List
Related Companies and Tools
This page (NASDAQ:FNCH) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy FNCH Stock Free FNCH Stock Alerts